|
Volumn 2, Issue 6, 2001, Pages 254-256
|
Comments on ALLHAT and doxazosin
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;
AMLODIPINE;
ANTIHYPERTENSIVE AGENT;
ANTILIPEMIC AGENT;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
CALCIUM CHANNEL BLOCKING AGENT;
CHLORTALIDONE;
CLONIDINE;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
DIURETIC AGENT;
DOXAZOSIN;
HYDRALAZINE;
LISINOPRIL;
PLACEBO;
RAMIPRIL;
RESERPINE;
TROGLITAZONE;
CLINICAL PRACTICE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG INDICATION;
DRUG LABELING;
DRUG TOLERANCE;
DRUG WITHDRAWAL;
FOLLOW UP;
HEALTH CARE;
HEALTH CARE POLICY;
HEART FAILURE;
HEART INFARCTION;
HUMAN;
HYPERTENSION;
ISCHEMIC HEART DISEASE;
LIVER TOXICITY;
MONOTHERAPY;
MORBIDITY;
MULTICENTER STUDY;
NOTE;
PRACTICE GUIDELINE;
PROSPECTIVE STUDY;
PUBLICATION;
STATISTICAL ANALYSIS;
STROKE;
|
EID: 0035702828
PISSN: 14686708
EISSN: None
Source Type: Journal
DOI: 10.1186/CVM-2-6-254 Document Type: Note |
Times cited : (7)
|
References (8)
|